WO2007081710A3 - Treatment modalities for autoimmune diseases - Google Patents

Treatment modalities for autoimmune diseases Download PDF

Info

Publication number
WO2007081710A3
WO2007081710A3 PCT/US2007/000082 US2007000082W WO2007081710A3 WO 2007081710 A3 WO2007081710 A3 WO 2007081710A3 US 2007000082 W US2007000082 W US 2007000082W WO 2007081710 A3 WO2007081710 A3 WO 2007081710A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoimmune diseases
treatment modalities
disclosed
methods
treatment
Prior art date
Application number
PCT/US2007/000082
Other languages
French (fr)
Other versions
WO2007081710A2 (en
Inventor
Matthew L Tripp
Jeffrey S Bland
Robert Lerman
Amy Hall
Veera Konda
Anu Desai
Original Assignee
Metaproteomics Llc
Matthew L Tripp
Jeffrey S Bland
Robert Lerman
Amy Hall
Veera Konda
Anu Desai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaproteomics Llc, Matthew L Tripp, Jeffrey S Bland, Robert Lerman, Amy Hall, Veera Konda, Anu Desai filed Critical Metaproteomics Llc
Priority to EP07717798A priority Critical patent/EP1993528A4/en
Priority to AU2007205224A priority patent/AU2007205224B2/en
Priority to JP2008549542A priority patent/JP2009525952A/en
Priority to MX2008008735A priority patent/MX2008008735A/en
Priority to NZ569513A priority patent/NZ569513A/en
Priority to CA002636142A priority patent/CA2636142A1/en
Publication of WO2007081710A2 publication Critical patent/WO2007081710A2/en
Publication of WO2007081710A3 publication Critical patent/WO2007081710A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Compositions of reduced isoalpha acids, vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Additional combinations including other compounds are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.
PCT/US2007/000082 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases WO2007081710A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP07717798A EP1993528A4 (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases
AU2007205224A AU2007205224B2 (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases
JP2008549542A JP2009525952A (en) 2006-01-06 2007-01-04 Methods for treating autoimmune diseases
MX2008008735A MX2008008735A (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases.
NZ569513A NZ569513A (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases comprising a reduced isoalpha acid compound
CA002636142A CA2636142A1 (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/326,874 US7718198B2 (en) 2001-06-20 2006-01-06 Treatment modalities for autoimmune diseases
US11/326,874 2006-01-06

Publications (2)

Publication Number Publication Date
WO2007081710A2 WO2007081710A2 (en) 2007-07-19
WO2007081710A3 true WO2007081710A3 (en) 2008-02-14

Family

ID=38256878

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/000082 WO2007081710A2 (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases
PCT/US2007/000137 WO2007081729A2 (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000137 WO2007081729A2 (en) 2006-01-06 2007-01-04 Treatment modalities for autoimmune diseases

Country Status (8)

Country Link
US (1) US7718198B2 (en)
EP (2) EP1993528A4 (en)
JP (1) JP2009525952A (en)
AU (2) AU2007205243A1 (en)
CA (2) CA2636142A1 (en)
MX (1) MX2008008735A (en)
NZ (1) NZ569513A (en)
WO (2) WO2007081710A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
EP1558271A4 (en) * 2002-10-21 2006-01-11 Metaproteomics Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
AU2004283065B2 (en) 2003-05-22 2009-11-26 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
WO2006053249A2 (en) * 2004-11-13 2006-05-18 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2
US20080248131A1 (en) * 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
AU2006321727A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and Acacia products
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
KR20090023722A (en) * 2006-06-20 2009-03-05 메타프로테오믹스, 엘엘씨 Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
CA2655990A1 (en) * 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
US8815306B2 (en) * 2007-03-19 2014-08-26 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
NZ581064A (en) 2007-05-11 2012-12-21 Metaproteomics Llc Methods and compositions for heavy metal detoxification
US20090060879A1 (en) * 2007-09-04 2009-03-05 The Procter & Gamble Company Oral Compositions, Products and Methods Of Use
MX2010006425A (en) * 2007-12-10 2010-08-31 Metaproteomics Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith.
CA2720546A1 (en) * 2008-04-02 2009-10-08 Metaproteomics, Llc. Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
GB2492680A (en) * 2010-03-17 2013-01-09 Arbonne Internat Llc Oral supplement
MX2012014521A (en) 2010-06-16 2013-05-20 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation.
ES2829388T3 (en) 2010-10-30 2021-05-31 Kindex Therapeutics Llc Cis 3,4-dihydroxy-2- (3-methylbutanoyl) -5 - (- 3-methylbutyl) -4- (4-methylpentanoyl) cyclopent-2-en-1-one derivatives, enantiomerically substantially pure compositions and methods
PL2723344T3 (en) * 2011-08-19 2016-03-31 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Monoterpene-containing agent for combination therapy
WO2013086323A2 (en) * 2011-12-08 2013-06-13 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
EP2969010B1 (en) * 2013-03-13 2017-10-11 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
KR20150135339A (en) 2013-03-13 2015-12-02 인플래머토리 리스폰스 리서치, 아이엔씨. Use of levocetirizine and montelukast in the treatment of traumatic injury
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
CN105126005A (en) * 2015-09-29 2015-12-09 成都倍加特生物科技有限公司 Internal administration medicament for treating alopecia areata and preparation method thereof
CA3043920A1 (en) * 2016-12-09 2018-06-14 Balchem Corporation Essential nutrients and related methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2175340A (en) * 1936-03-27 1939-10-10 New Discoveries Inc Vitaminizing malted liquors
US3933919A (en) * 1964-12-15 1976-01-20 Geoffrey Wilkinson Hydroformylation of mono-α-olefins and mono-α-acetylenes
GB1145240A (en) * 1965-03-01 1969-03-12 Kalamazoo Spice Extract Co Hop flavours for malt beverages and the like
US3451821A (en) * 1965-03-01 1969-06-24 Kalamazoo Spice Extract Co Increasing the utilization of hops and improving flavor control of malt beverages and the like
US3720517A (en) * 1970-12-21 1973-03-13 Hamm T Brewing Co Preparation of a fermented malt champagne
US3932603A (en) * 1971-05-28 1976-01-13 General Foods Corporation Oral preparations for reducing the incidence of dental caries
GB1372932A (en) 1971-03-15 1974-11-06 Gen Foods Corp Anti-caries compositions
US3965188A (en) * 1972-01-10 1976-06-22 Miller Brewing Company Hop extract process and product
CH617326A5 (en) * 1975-12-04 1980-05-30 Siegfried Ag
US4148873A (en) * 1976-11-05 1979-04-10 S. S. Steiner, Inc. Method for treating the skin with extracts of hops
US4170638A (en) * 1976-11-05 1979-10-09 S. S. Steiner, Inc. Method for producing a deodorant
US4123561A (en) * 1977-02-01 1978-10-31 S.S. Steiner, Inc. Method for processing hops for brewing
US4401684A (en) * 1981-10-01 1983-08-30 Australian Hop Marketers Pty. Ltd. Preservation of hops utilizing ascorbic acid
BE896610A (en) * 1982-05-06 1983-08-16 Hop Developments Ltd EXTRACTION OF PLANT MATERIAL USING CARBONIC ANHYDRIDE
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4644084A (en) * 1984-01-25 1987-02-17 Miller Brewing Company Preparation of tetrahydroisohumulones
GB2187755B (en) * 1984-02-28 1990-03-28 Kalamazoo Holdings Inc Separation of the constituents of co2 hop extracts
SU1247011A1 (en) 1985-02-20 1986-07-30 Специальное Конструкторское Бюро Химизации Научно-Производственного Объединения "Аэрозоль" Agent for hair care
US4767640A (en) * 1985-10-29 1988-08-30 Miller Brewing Company Light stable hop extracts and method of preparation
US4692280A (en) * 1986-12-01 1987-09-08 The United States Of America As Represented By The Secretary Of Commerce Purification of fish oils
JP2594787B2 (en) 1987-02-27 1997-03-26 大洋香料株式会社 Caries prevention agent
US5041300A (en) * 1987-04-03 1991-08-20 Kalamazoo Holdings, Inc. Hop flavor which is odor forming impurity free
US4956195A (en) * 1987-04-03 1990-09-11 Kalamazoo Holdings, Inc. Hop flavors wherein deleterious odor-forming impurities have been removed
US4778691A (en) * 1987-04-03 1988-10-18 Kalamazoo Holdings, Inc. Removal of deleterious odor-forming impurities from hop flavors
DE3712986A1 (en) * 1987-04-16 1988-10-27 Marbert Gmbh MEDICAL PREPARATIONS BASED ON TREASURE EXTRACT, METHOD FOR THE PRODUCTION THEREOF AND USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF COSMETIC PREPARATIONS AND A SPECIAL TREATMENT EXTRACT
US4857554A (en) * 1987-08-17 1989-08-15 Georgios Kallimanis Method for the treatment of psoriasis
US5082975A (en) * 1988-08-15 1992-01-21 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
US5166449A (en) * 1988-08-15 1992-11-24 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
DE3931147A1 (en) 1989-09-19 1991-03-28 Solong Natural Ltd New nerve tonic contg. extract of avena sativa - used to treat frigidity and increase libido in women
US5013571A (en) * 1990-01-31 1991-05-07 Pfizer Inc. Methods for making tetrahydroisoalpha and hexahydroisoalpha acids
EP0474892B1 (en) * 1990-09-10 1996-04-10 Fromm, Mayer-Bass Limited Process for the isomerisation of humulone in a carbon dioxide-hop extract and method for extracting the isohumulone
JP3155003B2 (en) 1990-11-06 2001-04-09 サントリー株式会社 Method for producing hop extract and hop extract obtained by the method
JP2514860B2 (en) 1990-11-30 1996-07-10 アサヒビール株式会社 Hop extract used for elimination of active oxygen and its utilization
RU2045995C1 (en) 1991-03-19 1995-10-20 Акционерное общество открытого типа "Волжский научно-исследовательский институт целлюлозно-бумажной промышленности" Drinking water filtering shell and method for production of this shell
TW199905B (en) * 1992-02-03 1993-02-11 J E Siebel Sons Company Inc Method and composition for enhancing foam properties of fermented malt beverages
US5641517A (en) * 1992-07-29 1997-06-24 Drymed As Composition comprising fertilized shell eggs
US5286506A (en) * 1992-10-29 1994-02-15 Bio-Technical Resources Inhibition of food pathogens by hop acids
US5296637A (en) * 1992-12-31 1994-03-22 Kalamazoo Holdings, Inc. Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerization
JPH06312924A (en) 1993-04-28 1994-11-08 Asahi Breweries Ltd Utilization of humulones having antioxidant action
JP3431250B2 (en) 1993-12-28 2003-07-28 日本臓器製薬株式会社 Beverage and method for producing the same
JP2677762B2 (en) * 1994-04-08 1997-11-17 株式会社神戸製鋼所 Oil-cooled compressor
DE69507185T2 (en) * 1994-04-12 1999-09-09 Hoechst Marion Roussel Inc Medicines used to treat osteoporosis
JPH0873369A (en) 1994-09-01 1996-03-19 Fuairudo:Kk Tea for health
JPH0967245A (en) 1995-08-28 1997-03-11 Asahi Breweries Ltd Bathing agent
US5827895A (en) * 1996-02-27 1998-10-27 Regents Of The University Of Minnesota Hexahydrolupulones useful as anticancer agents
US6020019A (en) * 1996-03-26 2000-02-01 Miller Brewing Company Hydrogenation of hop soft resins using CO2
JPH1025247A (en) 1996-07-10 1998-01-27 Asahi Breweries Ltd Preventive and therapeutic agent for gastritis and gastric and duodenal ulcer
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
JP4083831B2 (en) 1996-11-20 2008-04-30 株式会社カネボウ化粧品 Skin preparation
US5968539A (en) * 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
EP1059930B1 (en) 1998-03-04 2005-05-11 Nps Pharmaceuticals, Inc. Compositions comprising isovaleramide and ibuprofen
DE19841615A1 (en) 1998-09-11 2000-03-16 Fritz Armin Mueller Medicinal wine for alleviating pain and other symptoms of premenstrual syndrome, comprising mixture of extracts of different plants in dry white wine
ES2147538B1 (en) * 1999-01-29 2001-04-01 Revlon Consumer Prod Corp A CAPILLARY LOTION WITH IMPROVED PROPERTIES IN ITS HAIR PROTECTIVE AND PREVENTIVE ACTION OF HIS FALL, AND REDUCTION OF THE EXTERNAL EFFECTS OF ANDROGENETIC ALOPECIA AND WITH THAT OF THE HAIR FALL.
US6801860B1 (en) * 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US6383527B1 (en) * 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US20010031305A1 (en) 1999-05-07 2001-10-18 Michael Smith Hop extract of defined composition
MXPA01012390A (en) 1999-06-02 2003-10-14 Oxford Natural Products Plc Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe.
US6129907A (en) * 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
US6200594B1 (en) * 1999-12-29 2001-03-13 Vital Dynamics, Inc. Breast-enhancing, herbal compositions and methods of using same
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6583322B1 (en) * 2000-02-25 2003-06-24 Kalamazoo Holdings, Inc. Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the same
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
WO2001072265A1 (en) * 2000-03-31 2001-10-04 The Nisshin Oil Mills, Ltd. External preparation for the skin and beautifying agents
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
DE10031955A1 (en) 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing them
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US6908630B2 (en) * 2000-08-01 2005-06-21 Metaproteomics, Llc Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2
FR2815227B1 (en) * 2000-10-17 2003-04-11 Schwartz Laboratoires Robert ANTI-STRESS COMPOSITION FOR PRIMARY INCORPORATION IN NUTRITIONAL VEHICLES
WO2002060328A1 (en) 2001-01-31 2002-08-08 Rex Medical, Inc. Apparatus and method for stapling and resectioning gastro-esophageal tissue
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040219240A1 (en) * 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20030096027A1 (en) * 2001-10-26 2003-05-22 Babish John G. Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7144590B2 (en) * 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
AU2006321727A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and Acacia products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1993528A4 *

Also Published As

Publication number Publication date
WO2007081710A2 (en) 2007-07-19
US7718198B2 (en) 2010-05-18
MX2008008735A (en) 2008-09-12
AU2007205224B2 (en) 2013-03-28
US20070020352A1 (en) 2007-01-25
AU2007205224A1 (en) 2007-07-19
WO2007081729A3 (en) 2007-11-08
CA2635016A1 (en) 2007-07-19
EP2604262A1 (en) 2013-06-19
EP1993528A4 (en) 2010-07-28
WO2007081729A2 (en) 2007-07-19
CA2636142A1 (en) 2007-07-19
EP1993528A2 (en) 2008-11-26
NZ569513A (en) 2012-03-30
AU2007205243A1 (en) 2007-07-19
JP2009525952A (en) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2007081710A3 (en) Treatment modalities for autoimmune diseases
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007011962A3 (en) Treatment of cancer
WO2008156614A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008030883A3 (en) Treatment of cancer
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007059108A3 (en) Substituted quinolones and methods of use
WO2006086562A3 (en) Phenylazetidinone derivatives
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2009079585A3 (en) Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008070268A3 (en) Pharmaceutical compositions
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2007146335A3 (en) Compounds and compositions for treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007205224

Country of ref document: AU

Ref document number: 569513

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2636142

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/008735

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008549542

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007205224

Country of ref document: AU

Date of ref document: 20070104

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007717798

Country of ref document: EP